C12Y604/01001

Production of oxalyl-CoA, glyoxylate and/or glycolic acid

The present invention relates to a method of converting oxalate to oxalyl-coA and/or oxalyl-coA to glyoxylate in a fungus and to a method of producing glycolic acid. Still, the present invention relates to a genetically modified fungus comprising increased enzyme activity associated with oxalyl-CoA. And furthermore, the present invention relates to use of the fungus of the present invention for producing oxalate, oxalyl-coA, glyoxylate and/or glycolic acid from a carbon substrate. Still furthermore, the present invention relates to a method of producing specific products and to a method of preparing the genetically modified fungus of the present invention.

MICROORGANISMS AND METHODS FOR PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS AND RELATED COMPOUNDS
20210207178 · 2021-07-08 ·

The invention provides non-naturally occurring microbial organisms containing a fatty alcohol, fatty aldehyde or fatty acid pathway, wherein the microbial organisms selectively produce a fatty alcohol, fatty aldehyde or fatty acid of a specified length. Also provided are non-naturally occurring microbial organisms having a fatty alcohol, fatty aldehyde or fatty acid pathway, wherein the microbial organisms further include an acetyl-CoA pathway. In some aspects, the microbial organisms of the invention have select gene disruptions or enzyme attenuations that increase production of fatty alcohols, fatty aldehydes or fatty acids. The invention additionally provides methods of using the above microbial organisms to produce a fatty alcohol, a fatty aldehyde or a fatty acid.

Yeast cells having reductive TCA pathway from pyruvate to succinate and overexpressing an exogenous NAD(P)+ transhydrogenase enzyme

Yeast cells having a reductive TCA pathway from pyruvate or phosphoenolpyruvate to succinate, and which include at least one exogenous gene overexpressing an enzyme in that pathway, further contain an exogenous transhydrogenase gene.

FUNGAL CELLS FOR PRODUCTION OF FATTY ACIDS AND FATTY ACID-DERIVED PRODUCTS
20210095319 · 2021-04-01 ·

A fungal cell is capable of producing high levels of fatty acids and fatty acid-derived products. The fungal cell comprises at least one modification to the endogenous fatty acid metabolism.

<i>Escherichia coli </i>transformant for producing itaconate and uses thereof

The present disclosure provides an Escherichia coli transformant and a method for producing itaconate using the Escherichia coli transformant.

DIBASIC ORGANIC ACID PRODUCING STRAIN AND PREPARATION AND APPLICATION OF SAME

Provided are an engineered strain for synthesizing a dibasic organic acid and preparation and application of same. The engineered strain introduces or up-regulates expression of a positive regulator gene for synthesis of a dibasic organic acid, and/or down-regulates expression of a negative regulator gene for synthesis of a dibasic organic acid, as compared with the origin strain of the engineered strain, the producing capability for producing the dibasic organic acid is improved. The dibasic organic acid comprises malic acid, succinic acid, fumaric acid, oxaloacetic acid, glutaric acid, and adipic acid; the expression product of the positive regulator gene comprises aspartate aminotransferase, glutamic acid-aspartate transporter, C4-dicarboxylic acid transporter, pyruvate carboxylase and malate dehydrogenase, glucose transporter; the expression product of the negative regulatory gene comprises succinyl-CoA synthase, and malic acid-alpha ketoglutarate transporter, and the original strain comprises Myceliophthora thermophila, Thielavia terrestris, Aspergillus, and Rhizopus.

THERAPEUTIC COMPOSITIONS INCLUDING FRATAXIN, LACTOFERRIN, AND MITOCHONDRIAL ENERGY GENERATING ENZYMES, AND USES THEREOF
20200323947 · 2020-10-15 · ·

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2,6-dimethyl-Tyr-D-Arg-Phe-Lys-NH.sub.2, Phe-D-Arg-Phe-Lys-NH.sub.2, or D-Arg-2,6-Dmt-Lys-Phe-NH.sub.2.

ESCHERICHIA COLI TRANSFORMANT FOR PRODUCING ITACONATE AND USES THEREOF
20200325503 · 2020-10-15 ·

The present disclosure provides an Escherichia coli transformant and a method for producing itaconate using the Escherichia coli transformant.

Dibasic organic acid producing strain and preparation and application of same

Provided are an engineered strain for synthesizing a dibasic organic acid and preparation and application of same. The engineered strain introduces or up-regulates expression of a positive regulator gene for synthesis of a dibasic organic acid, and/or down-regulates expression of a negative regulator gene for synthesis of a dibasic organic acid, as compared with the origin strain of the engineered strain, the producing capability for producing the dibasic organic acid is improved. The dibasic organic acid comprises malic acid, succinic acid, fumaric acid, oxaloacetic acid, glutaric acid, and adipic acid; the expression product of the positive regulator gene comprises aspartate aminotransferase, glutamic acid-aspartate transporter, C4-dicarboxylic acid transporter, pyruvate carboxylase and malate dehydrogenase, glucose transporter; the expression product of the negative regulatory gene comprises succinyl-CoA synthase, and malic acid-alpha ketoglutarate transporter, and the original strain comprises myceliophthora thermophila, thielavia terrestris, aspergillus, and rhizopus.